Key facts
- Notable investors include IDG Capital, SND Ventures Group, Tianjin Venture Capital, BioTrack Capital, Huagai Capital — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for LMBio
- ·The full record, as it builds
Funding rounds
No funding rounds for LMBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LMBio
Developer and provider of cell-based immunotherapy products focused on tumor-infiltrating lymphocytes (TILs) for cancer treatment. The company provides innovative therapies and solutions, enabling the oncology industry to offer effective treatments for cancer patients.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2020
- Website
- lanmabio.com/
- Ownership
- Privately Held (backing)
LMBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LMBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LMBio in its N-PORT filings yet. We sweep new filings monthly.